Trial Profile

Phase 3 study of DARE-HRT1 in patients with moderate-to-severe Vasomotor Symptoms (VMS) due to Menopause

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 14 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Estradiol/progesterone (Primary)
Indications Menopausal syndrome; Vasomotor symptoms
Focus Registrational; Therapeutic Use

Most Recent Events

14 Aug 2023 New trial record
09 Aug 2023 According to a Dare Bioscience media release, the company intends to seek FDA approval of DARE-HRT1 for the treatment of moderate-to-severe VMS due to menopause in women with intact uteri.
09 Aug 2023 According to a Dare Bioscience media releas, the company Plans to Advance DARE-HRT1 into Single Phase 3 Efficacy Trial for Treatment of VMS due to Menopause.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com